ALKBH5‐modified UC‐MSCs‐derived exosomes (OE‐ALKBH5 Exo) inhibit the expression of M1 markers (iNOS, IL‐1β, TNF‐α, CD86) and enhance the expression of M2 markers (IL‐10, Arg‐1, CD206) by inhibiting the m6A methylation of TRAF6 and reducing its protein level and stability, thereby promoting M2 polarisation and alleviating the progression of DKD. The gene discussed is TRAF6; the disease is diabetic kidney disease.